142 related articles for article (PubMed ID: 24474335)
1. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Farsaci B; Jochems C; Grenga I; Donahue RN; Tucker JA; Pinto PA; Merino MJ; Heery CR; Madan RA; Gulley JL; Schlom J
Int J Cancer; 2014 Aug; 135(4):862-70. PubMed ID: 24474335
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Gulley JL; Heery CR; Madan RA; Walter BA; Merino MJ; Dahut WL; Tsang KY; Schlom J; Pinto PA
Cancer Immunol Immunother; 2013 Sep; 62(9):1521-31. PubMed ID: 23836412
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
[TBL] [Abstract][Full Text] [Related]
4. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
[TBL] [Abstract][Full Text] [Related]
6. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Kärjä V; Aaltomaa S; Lipponen P; Isotalo T; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4435-8. PubMed ID: 16334122
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
[TBL] [Abstract][Full Text] [Related]
8. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
9. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
[TBL] [Abstract][Full Text] [Related]
10. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.
Sanda MG; Smith DC; Charles LG; Hwang C; Pienta KJ; Schlom J; Milenic D; Panicali D; Montie JE
Urology; 1999 Feb; 53(2):260-6. PubMed ID: 9933036
[TBL] [Abstract][Full Text] [Related]
11. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Jochems C; Tucker JA; Tsang KY; Madan RA; Dahut WL; Liewehr DJ; Steinberg SM; Gulley JL; Schlom J
Cancer Immunol Immunother; 2014 Apr; 63(4):407-18. PubMed ID: 24514956
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Vergati M; Cereda V; Madan RA; Gulley JL; Huen NY; Rogers CJ; Hance KW; Arlen PM; Schlom J; Tsang KY
Cancer Immunol Immunother; 2011 Feb; 60(2):197-206. PubMed ID: 20976449
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
14. Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).
Merino MJ; Pinto PA; Moreno V; Gil S; Schlom J; Gulley JL
Hum Pathol; 2018 Aug; 78():72-78. PubMed ID: 29709495
[TBL] [Abstract][Full Text] [Related]
15. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Slavin-Chiorini DC; Catalfamo M; Kudo-Saito C; Hodge JW; Schlom J; Sabzevari H
Cancer Gene Ther; 2004 Oct; 11(10):665-80. PubMed ID: 15354200
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.
Pernot S; Terme M; Radosevic-Robin N; Castan F; Badoual C; Marcheteau E; Penault-Llorca F; Bouche O; Bennouna J; Francois E; Ghiringhelli F; De La Fouchardiere C; Samalin E; Baptiste Bachet J; Borg C; Boige V; Voron T; Stanbury T; Tartour E; Gourgou S; Malka D; Taieb J
Gastric Cancer; 2020 Jan; 23(1):73-81. PubMed ID: 31267360
[TBL] [Abstract][Full Text] [Related]
19. Serum antibodies to blood group A predict survival on PROSTVAC-VF.
Campbell CT; Gulley JL; Oyelaran O; Hodge JW; Schlom J; Gildersleeve JC
Clin Cancer Res; 2013 Mar; 19(5):1290-9. PubMed ID: 23362327
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
Front Immunol; 2019; 10():2353. PubMed ID: 31649669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]